-
公开(公告)号：KR1020160076511A
公开(公告)日：2016-06-30
申请号：KR1020160077299
申请日：2016-06-21
Applicant: 지엘팜텍주식회사
IPC: A61K36/282
CPC classification number: A61K36/282
Abstract: 본발명은탄소수 4의알코올류로추출하여얻은애엽추출물에대한것으로서, 기존기술에비해별도의제거공정을추가하지않더라도혈액응고억제물질이완전히제거된애엽추출물에대한것이다.
Abstract translation: 本发明涉及一种由碳数为4的醇提取的青蒿提取物，更具体地说，涉及与常规技术相比，即使不添加单独的去除方法，也完全除去抑制血液的材料的青蒿提取物。
-
公开(公告)号：KR1020120137998A
公开(公告)日：2012-12-24
申请号：KR1020110057227
申请日：2011-06-14
Applicant: 지엘팜텍주식회사
CPC classification number: A61K9/4825 , A61K31/145 , A61K31/58
Abstract: PURPOSE: A soft capsule formulation containing sustained release tamsulosin salts-containing granules and finasteride-containing powder is provided to ensure stability in a humid place. CONSTITUTION: A soft capsule formulation contains sustained release tamsulosin salts-containing granules and finasteride-containing powder. The amount of tamsulosin hydrochloride and finasteride is 0.1-0.8 mg and 1-5 mg, respectively. A method for manufacturing the sustained release tamsulosin particles comprises: a step of coating an inactive core with a drug and coating the upper end of the core with water-insoluble polymers of ethyl cellulose; a step of additionally coating the upper end with enteric polymers of methacrylic copolymer type C; and mixing sustained release particles without enteric coating and enteric sustained release particles. [Reference numerals] (AA) Drug elution(%) at 45 minutes; (BB) United States Pharmacopeia standard; (CC) Comparative embodiment 1; (DD) Embodiment 3; (EE) Time(months)
Abstract translation: 目的：提供含有持续释放的坦索罗辛盐颗粒和含有非那雄胺的粉末的软胶囊制剂，以确保在潮湿的地方的稳定性。 构成：软胶囊制剂含有含缓释坦索罗辛盐的颗粒和含有非那雄胺的粉末。 盐酸坦索罗辛和非那雄胺的量分别为0.1-0.8mg和1-5mg。 制备缓释坦索罗辛颗粒的方法包括：用药物涂覆无活性核心并用乙基纤维素的水不溶性聚合物涂覆芯的上端的步骤; 用C型甲基丙烯酸共聚物的肠溶聚合物另外涂覆上端的步骤; 并混合持续释放颗粒而没有肠溶和肠溶缓释颗粒。 （标号）（AA）药物洗脱（％）45分钟; （BB）美国药典标准; （CC）比较实施例1; （DD）实施例3; （EE）时间（月）
-
公开(公告)号：KR102258769B1
公开(公告)日：2021-06-01
申请号：KR1020180126933
申请日：2018-10-23
IPC: A23K20/189 , A23K40/30 , A23K20/158
-
公开(公告)号：KR101703352B1
公开(公告)日：2017-02-06
申请号：KR1020090001258
申请日：2009-01-07
Applicant: 지엘팜텍주식회사
IPC: A61K36/282 , A61P1/04
Abstract: 본발명은탄소수 4의알코올류로추출하여얻은애엽추출물에대한것으로서, 기존기술에비해별도의제거공정을추가하지않더라도혈액응고억제물질이완전히제거된애엽추출물에대한것이다.
Abstract translation: 提供没有血液凝固成分二孕酮的蒿草提取物，从艾蒿草药提取物中完全除去凝血成分，从而治疗过敏反应而没有副作用。 通过提取选自艾蒿（Artemisia argyi），A.藜（A.princeps var。）的青蒿草提取物，制备不含二肟菊的蒿草药提取物。 东方alis，，ana ana ana ana。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
-
Patent Agency Ranking
公开(公告)号：KR1020090010248A
公开(公告)日：2009-01-29
申请号：KR1020090001258
申请日：2009-01-07
Applicant: 지엘팜텍주식회사
IPC: A61K36/282 , A61P1/04
Abstract: The Artemisiae argyi herb extract having no blood clotting component dicumarol is provided to completely remove the blood clotting component from the Artemisiae argyi herb extract, thereby treating allergy response without side effects. The Artemisiae argyi herb extract containing no dicumarol is prepared by extracting Artemisiae argyi herb selected from Artemisia argyi, A. princeps var. orientalis, A. Montana and A. mongolica with alcohol having carbon number of 4 selected from 2-butanol, 1-butanol and 2-methyl-1-propanol, and filtering and concentrating the extract of Artemisiae argyi herb.
Abstract translation: 提供没有血液凝固成分二孕酮的蒿草提取物，从艾蒿草药提取物中完全除去凝血成分，从而治疗过敏反应而没有副作用。 通过提取选自艾蒿（Artemisia argyi），A.藜（A.princeps var。）的青蒿草提取物，制备不含二肟菊的蒿草药提取物。 东方alis，，ana ana ana ana。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
-
-
公开(公告)号：KR1020170058888A
公开(公告)日：2017-05-29
申请号：KR1020170046197
申请日：2017-04-10
Applicant: 지엘팜텍주식회사
IPC: A61K36/282
Abstract: 본발명은탄소수 4의알코올류로추출하여얻은애엽추출물에대한것으로서, 기존기술에비해별도의제거공정을추가하지않더라도혈액응고억제물질이완전히제거된애엽추출물에대한것이다.
Abstract translation: 本发明涉及作为通过用具有4个碳原子数，醇提取得到aeyeop提取物即使不添加比现有技术的单独去除步骤，所述抗凝血物质是完全除去aeyeop提取物。
-
公开(公告)号：KR1020110130373A
公开(公告)日：2011-12-05
申请号：KR1020110105157
申请日：2011-10-14
CPC classification number: A23K20/189 , A23K40/30
Abstract: PURPOSE: An enteric digestive enzyme composition, and a producing method thereof are provided to enable users to easily obtain the digestive enzyme composition using simple processes. CONSTITUTION: A producing method of an enteric digestive enzyme composition comprises a step of forming a coating layer of hydroxypropyl cellulose phthalate on granules containing an enzyme agent and hardening oil. The enzyme agent is formed by the solid-state fermentation. The hardening oil is obtained by adding hydrogen into liquid animal or vegetable oil, and has the melting point of 60-80 deg C.
Abstract translation: 目的：提供肠溶消化酶组合物及其制备方法，以使用户能够使用简单的方法容易地获得消化酶组合物。 构成：肠溶消化酶组合物的制造方法包括在含有酶试剂和硬化油的颗粒上形成羟丙基纤维素邻苯二甲酸酯的包衣层的工序。 酶试剂通过固态发酵形成。 硬化油通过向液体动物或植物油中加入氢而得到，熔点为60-80℃。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
